IP Library Granted Patent US 10,751,395
Granted Patent B2
US 10,751,395 · App. 15/957,494 · Granted Aug 25, 2020

Method of treating depression

Inventor: Eric Finzi (Chevy Chase, MD)
Assignee: Maryland Mental Health Institute, LLC
A61K38/4893A61K9/0019A61K31/135A61K31/137A61K31/4525A61K39/08A61K45/00A61K45/06C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,395
App. No.
15/957,494
Granted
Aug 25, 2020
Kind
B2
Abstract

Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.

Claims (24)

1. A method for treating a depressive disorder in a subject, comprising:

administering a therapeutically effective amount of a composition comprising a botulinum toxin to one or more facial muscle involved in frowning, scowling or a sad appearance; wherein the therapeutically effective amount is an amount sufficient to cause paralysis of the one or more facial muscle;

thereby treating the depressive disorder in the subject.

2. The method of claim 1 , wherein the one or more facial muscle involved in frowning, scowling or a sad appearance is selected from the group consisting of frontalis, orbicularis oculi, procerus, corrugator supercilii, and depressor anguli oris muscle.

3. The method of claim 1 , wherein the one or more facial muscle is a frontalis muscle, an orbicularis oculi muscle, or a procerus muscle.

4. The method of claim 1 , wherein the one or more facial muscle is a corrugator supercilii muscle, or a procerus muscle.

5. The method of claim 1 , wherein the botulinum toxin in the composition is selected from the group consisting of the botulinum toxins types A, B, C 1 , D, E, F and G.

6. The method of claim 5 , wherein the botulinum toxin in the composition is botulinum toxin A.

7. The method of claim 1 , wherein the therapeutically effective amount is about 5-60 Unit equivalents of a botulinum toxin type A.

8. The method of claim 7 , further comprising administering a second composition comprising an additional therapeutically effective amount of the botulinum toxin type A to the one or more facial muscle after about two to six months.

9. The method of claim 1 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

10. The method of claim 9 , wherein the additional modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression.

11. The method of claim 9 , wherein the additional modality of treatment comprises a selective serotonin reuptake inhibitor.

12. The method of claim 1 , wherein the depressive disorder is selected from the group consisting of a major depressive disorder, a dysthymic disorder and an atypical depressive disorder.

13. A method for treating psychotic major depression in a subject, comprising:

administering a therapeutically effective amount of a composition comprising a botulinum toxin to one or more facial muscle involved in frowning, scowling or a sad appearance; wherein the therapeutically effective amount is an amount sufficient to cause paralysis of the one or more facial muscle;

thereby treating the psychotic major depression in the subject.

14. The method of claim 13 , wherein the one or more facial muscle involved in frowning, scowling or a sad appearance is selected from the group consisting of frontalis, orbicularis oculi, procerus, corrugator supercilii, and depressor anguli oris muscle.

15. The method of claim 13 , wherein the one or more facial muscle is a frontalis muscle, an orbicularis oculi muscle, or a procerus muscle.

16. The method of claim 13 , wherein the one or more facial muscle is a corrugator supercilii muscle, or a procerus muscle.

17. The method of claim 13 , wherein the botulinum toxin in the composition is selected from the group consisting of the botulinum toxins types A, B, C 1 , D, E, F and G.

18. The method of claim 13 , wherein the therapeutically effective amount is about 5-60 Unit equivalents of a botulinum toxin type A.

19. The method of claim 13 , further comprising administering to the subject a therapeutically effective amount of an additional modality of treatment for depression.

20. The method of claim 9 , wherein the additional modality of treatment comprises administration of an antidepressant, psychotherapy, or a physical treatment for depression.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2024
From: MARYLAND MENTAL HEALTH INSTITUTE, LLC
To: HEALIS THERAPEUTICS, INC.
Reel/Frame 066178/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2019
From: FINZI, ERIC; ROSENTHAL, NORMAN E
To: MARYLAND MENTAL HEALTH INSTITUTE
Reel/Frame 050446/0153 →